

TABLE S1 Sequence Type Distribution of 139 CTX-M-producing *E. coli* isolates from different sources

Clonal complex	ST	Number of isolates					Phylogenetic group
		Water (n=26)	Pig (n=31)	Patient (n=36)	Healthy human (n=46)	Total (n=139)	
10	10	3	7	1	3	14	A
	48		2			2	A
	617	1	1			2	A
	43				1	1	A
23	23	1			1	2	A
	410			1		1	A
	88		1			1	A
86	641		2			2	B1
	453				1	1	B1
101	101		2			2	B1
168	93	1			1	2	A
177	155	1				1	B1
354	354			1	1	2	D
38	38	4		3	9	16	D
40	40			1		1	B1
405	405	2	1	2	1	6	D
46	46		1	1		2	A
95	95			1	1	2	B2
205	205	2				2	D
226	226				2	2	A
69	69				1	1	D
398	398		1			1	A
649	162		1			1	D
	62				2	2	D
	117		2			2	D
	131	4		10	6	20	B2
	295	1				1	B1
	361		1			1	B2
	457			2		2	D
	648	3		7	9	19	D
	697				1	1	A
	744			1	1	2	A
	746				1	1	A
	773				1	1	A
	1081		1			1	B1
	1112		1			1	A
	1193			3		3	B2
	1196		1			1	B1

	1684			1		1	A
	2003		2			2	D
	2035	1				1	A
	2345	1				1	B2
	3136	1				1	B2
	3177			1		1	D
New	3484	1				1	B2
New	3485	1				1	D
New	3724			1		1	B2
New	3725	1				1	A
New	3744	1				1	A
New	3745	1				1	A
New	3746	1				1	B1

TABLE S2 Distribution of CTX-M subgroups among 139 *E. coli* isolates from different sources

CTX-M type	Number of isolates					Phylogenetic group
	Water (n=26+2 ^a)	Pig (n=31+1 ^a)	Patient (n=36+3 ^a)	Healthy human (n=46+1 ^a)	Total (n=139+7 ^a)	
CTX-M-9 group	16	21	27	42	106	A,B1,B2,D
CTX-M-14	11	9	21	34	75	A,B1,B2,D
CTX-M-24		2	2	3	7	A,B1,B2,D
CTX-M-27	1	1	3	2	7	A, B2,D
CTX-M-65	4	5	1	3	13	A,B1,B2,D
CTX-M-98		2			2	A
CTX-M-104		1			1	D
CTX-M-121		1			1	B2
CTX-M-1 group	12	11	12	5	40	A,B1,B2,D
CTX-M-3	1		1	1	3	A,D
CTX-M-15	6		4	2	12	A, B2,D
CTX-M-55	5	11	6	2	24	A,B1,B2,D
CTX-M-123			1		1	A

^a: these isolates harbors both CTX-M-9 group and CTX-M-1 group ESBLs.

TABLE S3 Resistance rates of ESBLs-producing *E. coli* isolates and *p* values of various classifications^a

Antimicrobial agents	water isolates (N=26)	healthy human (N=46)	<i>p</i> ^b	pig feces (N=31)	hospitalized patients (N=36)	<i>p</i>	hospitalized patients (N=36)	healthy human (N=46)	<i>p</i>
ceftazidime	34.6	6.5	0.006	16.1	47.2	0.009	47.2	6.5	0.000
aztreonam	69.2	19.6	0.000	61.3	78.4	0.184	78.4	19.6	0.000
cefoxitin	19.2	0.0	0.005	0.0	11.1	0.118	11.1	0.0	0.034
cefepime	19.2	4.3	0.090	9.7	47.2	0.001	47.2	4.3	0.000
levofloxacin	76.9	37.0	0.001	48.4	88.9	0.000	88.9	37.0	0.000
moxifloxacin	76.9	41.3	0.006	48.4	88.9	0.000	88.9	41.3	0.000
cefoperazone/sulbactam	15.4	4.3	0.180	3.2	41.7	0.000	41.7	4.3	0.000
ciprofloxacin	76.9	41.3	0.006	48.4	88.9	0.000	88.9	41.3	0.000

TABLE S3 Resistance rates of ESBLs-producing *E. coli* isolates and *p* values of various classifications (**continued table**)

Antimicrobial agents	ST131 (N=20)	ST38 (N=16)	<i>p</i>	ST648 (N=19)	ST38 (N=16)	<i>p</i>	ST10 cplx (N=19)	ST38 (N=16)	<i>p</i>
aztreonam	65.0	18.8	0.008	31.6	18.8	0.460	63.2	18.8	0.016
levofloxacin	75.0	18.8	0.002	100.0	18.8	0.000	68.4	18.8	0.006
moxifloxacin	75.0	18.8	0.002	100.0	18.8	0.000	68.4	18.8	0.006

ciprofloxacin	75.0	18.8	0.002	100.0	18.8	0.000	68.4	18.8	0.006
---------------	------	------	--------------	-------	------	--------------	------	------	--------------

^a $p < 0.01$, the significant differences level. This table only shows the antibiotics with a significant difference, while the other antibiotics without significant differences were not included.